A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
15 May, 2025
Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer
LATEST NEWS: 15 May 2025 A novel imaging modality
21 April, 2025
Trial data-sharing made easier with HeSANDA initiative
Latest News: 21 April 2025 TROG Cancer Research is
